240 related articles for article (PubMed ID: 22370602)
1. Trends in therapy and survival of advanced stage epithelial ovarian cancer patients in the Netherlands.
van Altena AM; Karim-Kos HE; de Vries E; Kruitwagen RF; Massuger LF; Kiemeney LA
Gynecol Oncol; 2012 Jun; 125(3):649-54. PubMed ID: 22370602
[TBL] [Abstract][Full Text] [Related]
2. Treatment and outcome of elderly patients with advanced stage ovarian cancer: A nationwide analysis.
Schuurman MS; Kruitwagen RFPM; Portielje JEA; Roes EM; Lemmens VEPP; van der Aa MA
Gynecol Oncol; 2018 May; 149(2):270-274. PubMed ID: 29514738
[TBL] [Abstract][Full Text] [Related]
3. No improvement in long-term survival for epithelial ovarian cancer patients: A population-based study between 1989 and 2014 in the Netherlands.
Timmermans M; Sonke GS; Van de Vijver KK; van der Aa MA; Kruitwagen RFPM
Eur J Cancer; 2018 Jan; 88():31-37. PubMed ID: 29179135
[TBL] [Abstract][Full Text] [Related]
4. Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery.
Muraji M; Sudo T; Iwasaki S; Ueno S; Wakahashi S; Yamaguchi S; Fujiwara K; Nishimura R
Gynecol Oncol; 2013 Dec; 131(3):531-4. PubMed ID: 24096109
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of systematic lymph node dissection in advanced epithelial ovarian cancer during interval debulking surgery performed after neoadjuvant chemotherapy.
Eoh KJ; Yoon JW; Lee I; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
J Surg Oncol; 2017 Sep; 116(3):329-336. PubMed ID: 28542980
[TBL] [Abstract][Full Text] [Related]
6. Does neoadjuvant chemotherapy plus cytoreductive surgery improve survival rates in patients with advanced epithelial ovarian cancer compared with cytoreductive surgery alone?
Solmaz U; Mat E; Dereli ML; Turan V; Peker N; Tosun G; Dogan A; Adiyeke M; Ozdemir A; Gungorduk K; Sanci M; Yildirim Y
J BUON; 2015; 20(3):847-54. PubMed ID: 26214639
[TBL] [Abstract][Full Text] [Related]
7. [Re-evaluation of interval debulking surgery in advanced epithelial ovarian cancer].
Ma Y; Li Y; Cui H; Liang XD; Tang ZJ; Li XP; Zhao Y; Wei LH
Zhonghua Fu Chan Ke Za Zhi; 2012 May; 47(5):355-60. PubMed ID: 22883524
[TBL] [Abstract][Full Text] [Related]
8. Interval between debulking surgery and adjuvant chemotherapy is associated with overall survival in patients with advanced ovarian cancer.
Timmermans M; van der Aa MA; Lalisang RI; Witteveen PO; Van de Vijver KK; Kruitwagen RF; Sonke GS
Gynecol Oncol; 2018 Sep; 150(3):446-450. PubMed ID: 30001834
[TBL] [Abstract][Full Text] [Related]
9. Costs of treatment for elderly women with advanced ovarian cancer in a Medicare population.
Forde GK; Chang J; Ziogas A; Tewari K; Bristow RE
Gynecol Oncol; 2015 Jun; 137(3):479-84. PubMed ID: 25866323
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for septic adverse events and their impact on survival in advanced ovarian cancer patients treated with neoadjuvant chemotherapy and interval debulking surgery.
Son JH; Lee JH; Jung JA; Kong TW; Paek J; Chang SJ; Ryu HS
Gynecol Oncol; 2018 Oct; 151(1):32-38. PubMed ID: 30122310
[TBL] [Abstract][Full Text] [Related]
11. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.
Gill SE; McGree ME; Weaver AL; Cliby WA; Langstraat CL
Gynecol Oncol; 2017 Feb; 144(2):266-273. PubMed ID: 27916269
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage IIIC and IV).
Glasgow MA; Yu H; Rutherford TJ; Azodi M; Silasi DA; Santin AD; Schwartz PE
J Surg Oncol; 2013 Feb; 107(2):195-200. PubMed ID: 22648987
[TBL] [Abstract][Full Text] [Related]
13. Improved outcomes due to changes in organization of care for patients with ovarian cancer in the Netherlands.
Eggink FA; Mom CH; Kruitwagen RF; Reyners AK; Van Driel WJ; Massuger LF; Niemeijer GC; Van der Zee AG; Van der Aa MA; Nijman HW
Gynecol Oncol; 2016 Jun; 141(3):524-530. PubMed ID: 27090157
[TBL] [Abstract][Full Text] [Related]
14. Effect of adoption of neoadjuvant chemotherapy for advanced ovarian cancer on all cause mortality: quasi-experimental study.
Melamed A; Fink G; Wright AA; Keating NL; Gockley AA; Del Carmen MG; Schorge JO; Rauh-Hain JA
BMJ; 2018 Jan; 360():j5463. PubMed ID: 29298771
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors in epithelial ovarian cancer: A population-based study.
Chang LC; Huang CF; Lai MS; Shen LJ; Wu FL; Cheng WF
PLoS One; 2018; 13(3):e0194993. PubMed ID: 29579127
[TBL] [Abstract][Full Text] [Related]
16. Does neoadjuvant chemotherapy plus cytoreductive surgery improve survival rates in patients with advanced epithelial ovarian cancer compared with cytoreductive surgery alone?
Solmaz U; Mat E; Levent Dereli M; Turan V; Peker N; Tosun G; Dogan A; Adiyeke M; Ozdemir A; Gungorduk K; Sanci M; Yildirim Y
J BUON; 2015; 20(2):580-7. PubMed ID: 26011353
[TBL] [Abstract][Full Text] [Related]
17. The impact of lymph node dissection and adjuvant chemotherapy on survival: A nationwide cohort study of patients with clinical early-stage ovarian cancer.
Kleppe M; van der Aa MA; Van Gorp T; Slangen BF; Kruitwagen RF
Eur J Cancer; 2016 Oct; 66():83-90. PubMed ID: 27536891
[TBL] [Abstract][Full Text] [Related]
18. [Treatment and prognostic factors for stage IV epithelial ovarian cancer].
Wu M; Shen K; Lang J
Zhonghua Fu Chan Ke Za Zhi; 2000 Apr; 35(4):200-3. PubMed ID: 11776158
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center.
Mueller JJ; Zhou QC; Iasonos A; O'Cearbhaill RE; Alvi FA; El Haraki A; Eriksson AG; Gardner GJ; Sonoda Y; Levine DA; Aghajanian C; Chi DS; Abu-Rustum NR; Zivanovic O
Gynecol Oncol; 2016 Mar; 140(3):436-42. PubMed ID: 26777991
[TBL] [Abstract][Full Text] [Related]
20. The impact of geographic variations in treatment on outcomes in ovarian cancer.
Dehaeck U; McGahan CE; Santos JL; Carey MS; Swenerton KD; Kwon JS
Int J Gynecol Cancer; 2013 Feb; 23(2):282-7. PubMed ID: 23295939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
